Q1 Earnings Forecast for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Alumis in a report released on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($1.46) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Oppenheimer began coverage on Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Alumis in a research note on Wednesday. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Trading Up 23.0 %

Shares of Alumis stock opened at $4.92 on Tuesday. Alumis has a 1 year low of $3.18 and a 1 year high of $13.53. The company has a 50-day moving average of $5.49 and a 200 day moving average of $8.40.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. bought a new stake in shares of Alumis during the 3rd quarter valued at $1,160,000. BNP Paribas Financial Markets purchased a new position in Alumis during the third quarter valued at $27,000. MetLife Investment Management LLC bought a new stake in Alumis during the third quarter valued at about $89,000. Maven Securities LTD increased its position in Alumis by 100.0% in the third quarter. Maven Securities LTD now owns 50,000 shares of the company’s stock worth $534,000 after buying an additional 25,000 shares in the last quarter. Finally, Samsara BioCapital LLC bought a new position in shares of Alumis in the third quarter worth about $34,886,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.